Wedbush Predicts Weaker Earnings for Keros Therapeutics

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities research analysts at Wedbush reduced their Q2 2025 earnings per share estimates for shares of Keros Therapeutics in a research report issued on Wednesday, May 7th. Wedbush analyst Y. Zhong now anticipates that the company will post earnings per share of ($1.35) for the quarter, down from their prior estimate of ($1.27). Wedbush has a “Neutral” rating and a $15.00 price objective on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. Wedbush also issued estimates for Keros Therapeutics’ Q3 2025 earnings at ($1.34) EPS, Q4 2025 earnings at ($1.32) EPS, FY2025 earnings at ($0.42) EPS, FY2026 earnings at ($5.32) EPS, FY2027 earnings at ($4.99) EPS, FY2028 earnings at ($4.18) EPS and FY2029 earnings at ($3.72) EPS.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $211.25 million for the quarter, compared to analysts’ expectations of $84.62 million. During the same period in the previous year, the business earned ($1.21) earnings per share.

KROS has been the subject of a number of other research reports. Wells Fargo & Company cut their price objective on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, February 27th. HC Wainwright decreased their price target on Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday. Scotiabank cut their price objective on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a report on Thursday, January 16th. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Finally, Piper Sandler decreased their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.67.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $13.65 on Friday. The company has a market capitalization of $554.39 million, a P/E ratio of -2.62 and a beta of 1.32. Keros Therapeutics has a 12 month low of $9.12 and a 12 month high of $72.37. The company’s 50 day simple moving average is $12.20 and its 200 day simple moving average is $24.47.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. FNY Investment Advisers LLC acquired a new position in shares of Keros Therapeutics during the 1st quarter worth about $25,000. CWM LLC boosted its position in shares of Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after acquiring an additional 2,641 shares during the period. AlphaQuest LLC grew its stake in shares of Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after acquiring an additional 2,964 shares during the last quarter. Virtus ETF Advisers LLC increased its position in Keros Therapeutics by 107.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after acquiring an additional 1,998 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in Keros Therapeutics during the 4th quarter valued at $90,000. Institutional investors own 71.56% of the company’s stock.

Insiders Place Their Bets

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the company’s stock in a transaction dated Wednesday, April 9th. The shares were bought at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the transaction, the insider now directly owns 4,392,737 shares in the company, valued at $44,498,425.81. This trade represents a 27.01 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 20.60% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.